Aeglea BioTherapeutics, Inc. (AGLE) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Austin, TX, United States. The current CEO is Jonathan D. Alspaugh.
AGLE has IPO date of 2016-04-07, 69 full-time employees, listed on the NASDAQ Global Market, a market capitalization of $48.63M.
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
